Evidence map›Paper›PMID 40688657›Full record

ArticleMaterials today. Bio2025

Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment.

Carla Garcia-Mazas, Elia Bozzato, Jhonathan Angel Araujo Fernandez, Federico Quattrini, Veronique Preat, Laura Sanchez, Noemi Csaba, Marcos Garcia-Fuentes

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Polyphosphazene-Based Nanotherapeutics.Journal of functional biomaterials · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carla Garcia-MazasDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Center and Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Elia BozzatoUCLouvain, Advanced Drug Delivery and Biomaterials Research Group, Louvain Drug Research Institute (LDRI), Avenue Mounier 73/B1.73.12, 1200, Brussels, Belgium.
Jhonathan Angel Araujo FernandezZebrafish Laboratory, Department of Translational Medicine, FCM, UNICAMP, Campinas, Brazil.
Federico QuattriniDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Center and Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Veronique PreatUCLouvain, Advanced Drug Delivery and Biomaterials Research Group, Louvain Drug Research Institute (LDRI), Avenue Mounier 73/B1.73.12, 1200, Brussels, Belgium.
Laura SanchezDepartment of Zoology, Genetics & Physical Anthropology, University of Santiago de Compostela, 27002, Lugo, Spain.
Noemi CsabaDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Center and Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Marcos Garcia-FuentesDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Center and Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy presents promising opportunities to target critical pathways in complex cancers like glioblastoma multiforme, though it necessitates the use of efficient delivery vectors. Polyphosphazenes (PPZs) are highly flexible materials that lead to biodegradable, high-performance materials in various applications, including gene delivery. In this work, we synthesized various PPZ derivatives, incorporating primary amines, secondary amines, hydrophilic, and hydrophobic groups, and evaluated their gene transfection capabilities in combination with an anionic polyphosphazene (6MHA-PPZ) that acts as a charge quencher and transfection enhancer. Combining 6MHA-PPZ with a hydrophobic polymer demonstrated the highest gene delivery efficiency and safety, significantly surpassing previous benchmarks. Using these optimized nanoparticles, we delivered a BMP4-expressing plasmid (pBMP4) in glioblastoma models. The pBMP4 nanoparticles, when combined with the chemotherapeutic agent temozolomide (Tz), resulted in significant reductions in tumor volume, improved survival rates in preclinical models, and normalized the expression of drug resistance markers, providing a synergistic antitumoral effect with Tz. This study highlights the potential of PPZ-based nanoparticles for gene delivery and suggests that the combination of pBMP4-NPs and Tz could offer a promising therapeutic strategy for treating glioblastoma.

Indexed as

Advanced therapiesBMPGene deliveryGlioblastomaPolyphosphazenesSmart polymers

Identifiers

PMID40688657
PMCPMC12271426

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.